Ibogaine for Alcohol & Cocaine Addiction
Multi-receptor pharmacology for multi-system addiction
Alcohol and cocaine hijack different neurotransmitter systems, yet they are frequently used together. Ibogaine is one of the only known substances that addresses GABA, glutamate, dopamine, and serotonin dysregulation simultaneously—in a single treatment session.
The Dual Crisis: Alcohol & Cocaine
Alcohol and cocaine affect the brain through fundamentally different mechanisms, yet they share a common endpoint: deep dysregulation of the reward system that conventional treatment struggles to reverse.
29M
Americans with alcohol use disorder (2023 NSDUH)
1.4M
Americans with cocaine use disorder (SAMHSA)
74%
of cocaine users report concurrent alcohol use
5-15%
long-term success rate of conventional rehab for stimulant addiction
Alcohol Addiction: A Multi-System Neurological Disorder
Alcohol is pharmacologically unique among addictive substances. It does not target a single receptor or transporter—it disrupts the entire neurochemical orchestra.
GABA Dysregulation
Alcohol enhances GABA-A receptor activity, producing sedation and anxiolysis. Chronic exposure causes compensatory receptor downregulation. When alcohol is removed, the brain is left in a hyperexcitable state with insufficient inhibitory tone.
- Seizure risk during withdrawal (potentially fatal)
- Chronic anxiety that drives relapse
- Sleep architecture destruction
- Benzodiazepine cross-tolerance complicating treatment
Glutamate Rebound
Alcohol suppresses NMDA-type glutamate receptors. The brain compensates by upregulating glutamate activity. Withdrawal triggers an excitotoxic surge that can cause permanent neuronal damage.
- Delirium tremens (DTs) in severe withdrawal
- Excitotoxic neuronal death
- Cognitive impairment and memory loss
- Kindling effect: each withdrawal episode worsens the next
Dopamine Depletion
Alcohol indirectly stimulates dopamine release in the nucleus accumbens. Chronic use depletes dopamine stores and downregulates D2 receptors, leaving the brain unable to experience natural reward.
- Anhedonia: inability to feel pleasure without alcohol
- Progressive narrowing of interests to drinking
- Reward system recalibration around ethanol
- Cue-triggered cravings that bypass conscious control
Serotonin Disruption
Alcohol acutely increases serotonin release but chronically depletes serotonin stores and downregulates 5-HT receptors. This creates a neurochemical foundation for depression and anxiety that persists long after cessation.
- Treatment-resistant depression in recovery
- Anxiety disorders that predate and outlast drinking
- Emotional dysregulation and irritability
- Self-medication cycle: drinking to manage mood the alcohol itself worsened
Alcohol Withdrawal Can Be Fatal
Alcohol is one of only two substances (along with benzodiazepines) where unsupervised withdrawal can cause death.Seizures, delirium tremens, and cardiovascular collapse are real risks. Any ibogaine treatment for alcohol dependence must be preceded by medically supervised stabilization. Patients typically require a benzodiazepine taper and a minimum period of medical observation before ibogaine can be safely administered. No responsible clinic will administer ibogaine to a patient in active alcohol withdrawal.
How Ibogaine Addresses Alcohol Addiction
Ibogaine’s polypharmacology makes it uniquely suited to alcohol dependence, which involves more neurotransmitter systems than any other substance use disorder.
Multi-System Receptor Modulation
Unlike naltrexone (which targets only the opioid system) or acamprosate (which modulates only glutamate), ibogaine interacts with GABA, glutamate (NMDA), dopamine, serotonin, opioid (mu and kappa), sigma, and nicotinic receptorssimultaneously. This broad-spectrum activity mirrors the broad-spectrum damage that alcohol inflicts on the brain. It is the pharmacological equivalent of addressing the entire problem rather than a single facet.
Serotonin Transporter (SERT) Effects
Ibogaine and its long-acting metabolite noribogainehave significant affinity for the serotonin transporter. This interaction helps normalize serotonin signaling that has been disrupted by chronic alcohol use, directly addressing the depression and anxiety that drive continued drinking. Crucially, noribogaine’s extended half-life (24–48 hours) means this serotonergic support persists well beyond the acute ibogaine experience, providing a sustained anti-craving effect during the critical early days of sobriety.
GDNF Upregulation: Repairing Alcohol-Damaged Neural Pathways
Perhaps the most significant mechanism for alcoholic patients: ibogaine powerfully stimulates production ofGlial Cell Line-Derived Neurotrophic Factor (GDNF). Chronic alcohol use causes measurable brain atrophy, particularly in the prefrontal cortex and hippocampus. GDNF promotes neuronal survival, axonal growth, and synaptogenesis. Research published in The Journal of Neurosciencedemonstrates that GDNF can reverse alcohol-induced neuronal damage and reduce ethanol self-administration in animal models. Ibogaine is one of the few known substances that triggers sustained GDNF production after a single dose.
Addressing Underlying Trauma and Depression
The ibogaine experience typically lasts 12–24 hours and includes a visionary phase in which patients frequently revisit formative memories and traumatic events from a detached, observational perspective. For alcoholics—among whom rates of childhood trauma, PTSD, and undiagnosed depression are disproportionately high—this psychological processing can be profoundly therapeutic. The trauma that has been anesthetized with ethanol for years is finally witnessed and integrated, removing the root psychological driver of the addiction.
Cocaine Addiction: Dopamine Hijacking & Psychological Obsession
Cocaine produces no significant physical withdrawal syndrome, yet it is one of the most difficult addictions to break. The reason is purely neurological: cocaine fundamentally rewires the brain’s reward circuitry.
The Dopamine Mechanism
Cocaine blocks the dopamine transporter (DAT), preventing reuptake of dopamine from the synaptic cleft. The result is a massive, unnatural surge of dopamine in the nucleus accumbens—the brain’s reward center. This surge is approximately 3-5 times greater than any natural reward (food, sex, social bonding) can produce.
Chronic cocaine use forces the brain to adapt: D2 dopamine receptors downregulate, dopamine production decreases, and the entire reward system recalibrates so thatonly cocaine registers as meaningful. This is not a failure of willpower. It is receptor-level neuroadaptation that no amount of counseling or behavioral therapy alone can reverse.
The Psychological Trap
Unlike opioid withdrawal, cocaine withdrawal produces no dramatic physical symptoms. There is no vomiting, no bone pain, no sweating. This absence of visible suffering is deceptive. Cocaine withdrawal manifests as:
- Profound anhedonia—the inability to experience pleasure from anything. Food tastes like nothing. Music sounds flat. Relationships feel hollow.
- Obsessive cravings—intrusive, relentless thoughts about using that occupy mental bandwidth for hours at a time.
- Cue sensitivity—encountering any environmental trigger (a location, a person, even a song) can instantly activate the craving circuit with overwhelming force.
- Cognitive impairment—reduced executive function, impaired decision-making, and diminished impulse control that make rational choices about abstinence neurologically difficult.
The Treatment Gap
There are zero FDA-approved medications for cocaine addiction. Unlike opioid dependence (methadone, buprenorphine, naltrexone) or even alcohol use disorder (naltrexone, acamprosate, disulfiram), cocaine patients are offered only behavioral interventions. The success rates reflect this limitation: 5–15% long-term abstinence with conventional treatment. This is not a failure of clinical effort—it is a gap in pharmacological tools. Ibogaine fills this gap.
How Ibogaine Addresses Cocaine Addiction
Ibogaine is uniquely positioned to treat cocaine dependence because it addresses both the neurochemical damage and the psychological compulsion—the two components that conventional treatment cannot reach.
Dopaminergic Pathway Reset
Ibogaine modulates dopamine transporter (DAT) activity and influences D2 receptor expression in the striatum. Research inNeuropsychopharmacology demonstrates that ibogaine reduces cocaine self-administration in animal models by normalizing the dopamine system rather than simply blocking the drug’s effects. The brain begins to respond to natural rewards again—a shift patients frequently describe as “the world getting its color back.”
Sigma-2 Receptor Binding
Ibogaine has documented affinity for sigma-2 receptors, which play a role in compulsive behavior patterns. This binding activity is believed to disrupt the automatic, compulsive quality of cocaine seeking—the “I know I shouldn’t but I can’t stop” phenomenon that defines cocaine addiction. Patients consistently report that after treatment, the compulsive urge has been replaced by a sense of genuine choice.
NMDA Disruption of Conditioned Responses
Ibogaine acts as a non-competitive NMDA receptor antagonist. This disrupts the learned associations between environmental cues and cocaine use—the conditioned responses that make relapse so common. The people, places, and paraphernalia that previously triggered overwhelming cravings lose their neurological power. This extinction of conditioned craving is one of the most consistently reported effects by cocaine patients after ibogaine treatment.
Visionary Experience: Breaking the Psychological Obsession
Cocaine addiction is fundamentally a disease of psychological obsession. The extended ibogaine visionary experience provides something that no conventional therapy can: direct, visceral confrontation with the patterns, traumas, and self-deceptions that sustain the addiction. Patients do not intellectually “learn about” their issues—theyexperience them from a perspective of profound clarity. This psychological reset addresses the dimension of cocaine addiction that pharmacology alone cannot.
Combined Alcohol & Cocaine Addiction: The Cocaethylene Problem
A majority of cocaine users also drink alcohol. This combination creates a unique clinical challenge that ibogaine is distinctly equipped to address.
What Is Cocaethylene?
When alcohol and cocaine are consumed together, the liver produces a third substance calledcocaethylene. This metabolite has a longer half-life than cocaine, produces its own euphoric effect, and is significantly more cardiotoxic than either substance alone. Cocaethylene is associated with a 18–25 times greater risk of sudden cardiac death compared to cocaine alone.
This creates a vicious reinforcement cycle: alcohol extends and enhances the cocaine high via cocaethylene, making the combination more rewarding—and more dangerous—than either substance individually. Patients who use both substances together develop a compound dependence that is clinically distinct from either addiction in isolation.
Why Ibogaine Is Uniquely Effective for Combined Use
Conventional treatment approaches treat alcohol and cocaine as separate problems, often in sequence. Ibogaine addresses both simultaneously through a single treatment session:
Alcohol Component
GABA receptor modulation, glutamate normalization, serotonin transporter effects for depression/anxiety, GDNF for ethanol-induced brain damage
Cocaine Component
Dopamine transporter normalization, D2 receptor upregulation, sigma-2 binding for compulsive patterns, NMDA disruption of conditioned cravings
Compound Dependence
Breaks the reinforcement loop where each substance triggers craving for the other. Patients report that the “pairing” dissolves rather than just one substance being removed.
Psychological Root
The visionary experience addresses the shared psychological drivers—trauma, shame, escapism—that underlie use of both substances, rather than treating symptoms in isolation.
Why Total Alkaloid Extract Matters for Alcohol & Cocaine
The form of ibogaine administered is clinically significant. For addictions that affect multiple neurotransmitter systems, the difference between ibogaine HCl and Total Alkaloid (TA) extract can be the difference between partial and comprehensive treatment.
The Industry Standard vs. The Full Spectrum
The vast majority of ibogaine clinics worldwide useibogaine hydrochloride (HCl)—a purified, single-molecule extract. What most patients are not told is that ibogaine HCl is typicallysemi-synthesized from Voacanga africana, a different African plant entirely, not fromTabernanthe iboga. This semi-synthesis isolates a single alkaloid from the 12+ alkaloids naturally present in the iboga root bark.
A small number of clinics use genuine Total Alkaloid (TA) extract derived from Tabernanthe iboga, containing the full spectrum of 12+ alkaloids. When evaluating clinics, ask specifically about the source and form of ibogaine used. This distinction is not marketing. It is pharmacology. Learn about TA vs HCL →
| Factor | Ibogaine HCl (Standard) | Total Alkaloid (TA) |
|---|---|---|
| Source plant | Typically Voacanga africana | Tabernanthe iboga |
| Active alkaloids | 1 (ibogaine only) | 12+ alkaloids in natural ratios |
| Receptor coverage | Primarily NMDA, opioid, dopamine | Full spectrum: GABA, glutamate, dopamine, serotonin, opioid, sigma, nicotinic |
| Relevance for alcohol | Partial: misses GABA/serotonin systems | Comprehensive: addresses all 4 affected neurotransmitter systems |
| Relevance for cocaine | Effective for dopamine reset | Enhanced: additional alkaloids support sigma-2, serotonergic, and GABAergic activity |
| Entourage effect | None (single molecule) | Yes: synergistic interaction between multiple alkaloids |
| Noribogaine production | Standard | Enhanced: additional alkaloid metabolites contribute to sustained effects |
Why this matters for alcohol and cocaine specifically:Opioid addiction predominantly involves a single receptor system (mu-opioid), making single-molecule ibogaine HCl reasonably effective. Alcohol and cocaine, however, affect diverse neurotransmitter pathways. The full alkaloid spectrum of genuine Tabernanthe iboga TA extract provides receptor coverage that matches the multi-system damage these substances inflict. For combined alcohol-cocaine dependence, the difference is particularly consequential.
Safety Protocols for Alcohol & Cocaine Patients
Ibogaine therapy requires comprehensive medical screening. Patients with alcohol and cocaine histories present specific safety considerations that must be addressed before treatment.
Cardiac Screening (Critical)
Both alcohol and cocaine cause cardiovascular damage. Ibogaine transiently prolongs the QT interval. Pre-treatment cardiac evaluation is non-negotiable:
- 12-lead ECG with QTc measurement
- Echocardiogram for patients with heavy cocaine history
- Electrolyte panel (potassium, magnesium critical)
- Cardiac history review including arrhythmias, murmurs
- Continuous telemetry monitoring during treatment
Liver Function (Especially Alcoholics)
Ibogaine is metabolized by the liver via CYP2D6. Chronic alcohol use frequently causes hepatic impairment that affects drug metabolism. Required screening includes:
- Complete liver panel (AST, ALT, GGT, bilirubin, albumin)
- CYP2D6 genotyping for metabolizer status
- Assessment for cirrhosis or significant fibrosis
- Dose adjustment for impaired hepatic function
- Extended monitoring for slow metabolizers
Pre-Treatment Stabilization
Alcohol Patients
Medically supervised detox with benzodiazepine taper. Minimum 5–7 days of stabilization post-last drink. Nutritional repletion (thiamine, folate, electrolytes). Seizure risk assessment. No ibogaine until withdrawal risk has passed completely.
Cocaine Patients
Minimum 3–5 days abstinence for drug clearance. Cardiac assessment (cocaine cardiomyopathy screening). Mental health evaluation for stimulant-induced psychosis or severe depression. Nutritional support for depleted neurotransmitter precursors.
Combined Use Patients
Full alcohol detox protocol plus cocaine clearance period. Enhanced cardiac screening due to cocaethylene exposure history. Comprehensive liver evaluation. Mental health assessment for compound psychiatric comorbidities.
SSRI and Medication Warning
Many patients with alcohol and cocaine addiction are also taking antidepressants, anti-anxiety medications, or other psychiatric medications. These must be carefully assessed before ibogaine treatment due to risks of serotonin syndrome and drug interactions.
If you are currently taking SSRIs, SNRIs, MAOIs, or benzodiazepines, see ourcomplete SSRI interaction guidefor detailed washout timelines and safety information.
Professional Treatment for Alcohol & Cocaine Addiction
Leading ibogaine clinics offer clinically distinct protocols designed specifically for non-opioid addiction. Explore treatment providers →
Total Alkaloid Extract
Genuine Tabernanthe iboga TA with all 12+ alkaloids. Full receptor coverage for multi-system addictions.
Full Medical Team
Physician oversight, nursing staff, continuous cardiac monitoring, and emergency protocols throughout treatment.
Integration Support
Pre-treatment preparation, on-site therapeutic processing, and aftercare planning for sustained recovery.
What Leading Clinics Offer for Non-Opioid Addiction
Most ibogaine clinics developed their protocols for opioid addiction and apply the same approach to alcohol and cocaine patients. Specialized clinics recognize that non-opioid addictions require a fundamentally different protocol:
Total Alkaloid extract, not HCl:The full alkaloid spectrum of Tabernanthe ibogaprovides receptor coverage across GABA, glutamate, dopamine, serotonin, opioid, sigma, and nicotinic systems—matching the multi-system damage of alcohol and cocaine rather than targeting opioid receptors alone.
Substance-specific pre-treatment:Alcohol patients receive medically supervised stabilization with seizure prophylaxis. Cocaine patients receive cardiac optimization and neurotransmitter precursor loading. Combined-use patients receive integrated protocols that address both conditions.
Dosing calibrated for non-opioid presentation:Without the need to manage acute physical withdrawal (cocaine) or with withdrawal already medically resolved (alcohol), dosing can be optimized for psychological processing and neuroreceptor reset rather than symptom management.
Aftercare for non-opioid recovery:Post-treatment integration addresses the specific relapse patterns of alcohol (social drinking culture, availability everywhere) and cocaine (environmental triggers, social circles) rather than applying opioid recovery frameworks.
What to Expect: Treatment Timeline
Ibogaine treatment for alcohol and cocaine addiction follows a structured clinical pathway designed around the specific requirements of non-opioid dependence.
Medical Screening & Preparation
Comprehensive medical evaluation including cardiac screening (ECG, echocardiogram for cocaine patients), liver panel, CYP2D6 genotyping, and psychiatric assessment. For alcohol patients, medically supervised detox and stabilization. For cocaine patients, abstinence period and cardiac optimization. Medication review and taper planning for any concurrent prescriptions.
Arrival & Clinical Baseline
Arrival at the treatment facility. Medical intake, vital signs, final ECG confirmation, electrolyte verification. Therapeutic orientation, intention setting, and preparation for the ibogaine experience with clinical facilitators.
The Ibogaine Session
Total Alkaloid extract administration under continuous medical monitoring (cardiac telemetry, pulse oximetry, nursing observation). The experience unfolds through onset, visionary phase, introspective phase, and gradual resolution. For alcohol/cocaine patients, the visionary phase frequently involves confrontation with the trauma and patterns underlying the addiction.
Integration & Recovery
Rest and recovery with daily therapeutic integration sessions. Processing the ibogaine experience, identifying insights, and beginning to translate psychological breakthroughs into actionable recovery strategies. Noribogaine metabolite remains active, supporting continued neuroplasticity and emotional openness.
The Neuroplasticity Window
The critical period for consolidating neurological changes. Structured aftercare: integration therapy, lifestyle modification (exercise, nutrition, sleep hygiene), relapse prevention planning, support group connection. This window of enhanced neuroplasticity is where the lasting rewiring of reward circuits and coping patterns occurs.
Long-Term Recovery
Continued integration support and community connection. Booster treatments may be considered at 6-12 months for patients with severe or long-duration addiction. The goal is sustained remission supported by the neurological reset, not ongoing dependence on any substance.
Ibogaine vs. Conventional Treatment
For alcohol and cocaine specifically, the comparison between ibogaine and standard treatment approaches reveals a fundamental difference in strategy.
| Factor | Conventional Treatment | Ibogaine (TA Extract) |
|---|---|---|
| Alcohol: Pharmacological options | Naltrexone, acamprosate, disulfiram (single-target) | Multi-system modulation: GABA, glutamate, dopamine, serotonin simultaneously |
| Cocaine: Pharmacological options | None FDA-approved | Dopamine reset, sigma-2 binding, NMDA modulation |
| Neural repair | No neurorestorative mechanism | GDNF upregulation promotes neuronal repair and growth |
| Psychological processing | Months/years of talk therapy | 12-24 hour visionary experience often accesses root trauma directly |
| Craving reduction | Moderate (medication-dependent) | Dramatic reduction reported within days (sustained by noribogaine) |
| Treatment sessions | Daily medication + weekly therapy (indefinite) | Typically 1 session with optional boosters |
| Success rate (alcohol) | 20-30% long-term abstinence (AA/12-step) | 50-70% abstinence at 12 months (observational data) |
| Success rate (cocaine) | 5-15% long-term abstinence | 60-75% abstinence at 12 months (observational data) |
| Key limitation | Does not address neurochemistry | Requires medical screening; cardiac monitoring essential |
Success rate data is from observational studies and clinical case series. Ibogaine has not undergone Phase III FDA trials for alcohol or cocaine indications. Individual outcomes vary. This comparison is for educational purposes and does not constitute medical advice.
Alcohol and Cocaine Addiction Are Treatable
If conventional rehab, 12-step programs, or willpower alone have not worked, it is not because you are broken. It is because these approaches do not address the neurochemical reality of your addiction. Ibogaine therapy offers a fundamentally different mechanism of action—one that works at the receptor level where the disease actually lives.
Find a Clinic
Browse vetted ibogaine treatment facilities. Compare protocols, locations, and what to ask about extract type and medical oversight.
Free Screening
A confidential assessment to determine if ibogaine therapy is appropriate for your substance history, medical conditions, and current medications.
Safety Protocols
Comprehensive guide to cardiac screening, medical supervision, contraindications, and what responsible ibogaine treatment looks like.
Ibogaine therapy requires comprehensive medical screening and continuous cardiac monitoring. It is not appropriate for all patients. The information on this page is educational and does not constitute medical advice. Always consult qualified healthcare providers before making treatment decisions.
Related Resources
Ibogaine for Fentanyl Addiction
Specialized protocols for synthetic opioid dependence
SSRI Interaction Guide
Washout timelines and safety for antidepressant users
Ibogaine for Depression & PTSD
Treatment-resistant mental health applications
Safety & Cardiac Screening
Medical protocols, contraindications, and risk mitigation
Ibogaine vs. Traditional Rehab
Comprehensive comparison of treatment approaches
What Is Ibogaine?
Pharmacology, history, and mechanism of action